Clinical trial
Qidong Hepatitis B Intervention Study
NCT00222664 · University of Oxford, Other · Completed
Key facts
| NCT number | NCT00222664 |
|---|---|
| Title | Qidong Hepatitis B Intervention Study |
| Lead sponsor | University of Oxford, Other |
| Collaborators | Cancer Institute and Hospital, Chinese Academy of Medical Sciences Qidong Liver Cancer Institute Merck Institute for Therapeutic Research |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B, Liver Neoplasms, Liver Diseases |
| Intervention type | Biological |
| Interventions | Hep-V Vax |
| Enrollment | 80,000 |
| Start date | Sep 1, 1983 |
| Completion | Dec 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 22, 2005 |
| Countries | China, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: